Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 4.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 15,832 shares of the company’s stock after buying an additional 696 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Omnicell were worth $553,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of OMCL. Alliancebernstein L.P. raised its holdings in shares of Omnicell by 4.3% in the 4th quarter. Alliancebernstein L.P. now owns 55,922 shares of the company’s stock worth $2,490,000 after buying an additional 2,316 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Omnicell by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 132,252 shares of the company’s stock worth $5,888,000 after buying an additional 28,390 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Omnicell by 2.4% in the 4th quarter. Invesco Ltd. now owns 219,453 shares of the company’s stock worth $9,770,000 after buying an additional 5,063 shares in the last quarter. Sterling Capital Management LLC raised its holdings in shares of Omnicell by 11.1% in the 4th quarter. Sterling Capital Management LLC now owns 12,838 shares of the company’s stock worth $572,000 after buying an additional 1,280 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its holdings in shares of Omnicell by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company’s stock worth $213,000 after buying an additional 307 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on OMCL. Benchmark dropped their price target on Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company raised their price target on Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, July 21st. Bank of America raised their price target on Omnicell from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, May 23rd. Piper Sandler set a $55.00 price target on Omnicell and gave the company an “overweight” rating in a report on Monday. Finally, Wall Street Zen cut Omnicell from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.71.
Omnicell Stock Down 0.6%
Shares of OMCL opened at $31.34 on Thursday. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of 62.68, a PEG ratio of 9.20 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. The business’s fifty day moving average price is $29.43 and its two-hundred day moving average price is $32.52. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.74.
Omnicell (NASDAQ:OMCL – Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $0.51 EPS. On average, analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current year.
About Omnicell
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Articles
- Five stocks we like better than Omnicell
- Investing in Construction Stocks
- 3 Earnings Reports Give a Snapshot of Consumer Sentiment
- What Investors Need to Know About Upcoming IPOs
- Amazon’s Bears Have Raised the White Flag—Get Excited
- How to invest in marijuana stocks in 7 steps
- Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL – Free Report).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.